Holford, M., Daly, M., King, G. F. & Norton, R. S. Venoms to the rescue. Science 361, 842–844 (2018).
Casewell, N. R., Wüster, W., Vonk, F. J., Harrison, R. A. & Fry, B. G. Advanced cocktails: the evolutionary novelty of venoms. Developments Ecol. Evol. 28, 219–229 (2013). A assessment of the pure historical past of venoms and mechanisms of venom evolution.
King, G. F. Venoms as a platform for human medicine: translating toxins into therapeutics. Professional Opin. Biol. Ther. 11, 1469–1484 (2011). This assessment covers all levels of the event of medication primarily based on animal venoms.
Herzig, V. et al. Animal toxins — nature’s evolutionary-refined toolkit for fundamental analysis and drug discovery. Biochem. Pharmacol. 181, 114096 (2020).
Pineda, S. S. et al. Structural venomics reveals evolution of a fancy venom by duplication and diversification of an historic peptide-encoding gene. Proc. Natl Acad. Sci. USA 117, 11399–11408 (2020).
Cid-Uribe, J. I., Veytia-Bucheli, J. I., Romero-Gutierrez, T., Ortiz, E. & Possani, L. D. Scorpion venomics: a 2019 overview. Professional Rev. Proteom. 17, 67–83 (2020).
Tasoulis, T. & Isbister, G. Ok. A assessment and database of snake venom proteomes. Toxins 9, 290 (2017). An evaluation of the composition and variety of snake venom.
Casewell, N. R. et al. Medically vital variations in snake venom composition are dictated by distinct postgenomic mechanisms. Proc. Natl Acad. Sci. USA 111, 9205–9210 (2014).
Massey, D. J. et al. Venom variability and envenoming severity outcomes of the Crotalus scutulatus scutulatus (Mojave rattlesnake) from southern Arizona. J. Proteom. 75, 2576–87 (2012).
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H. & Sunagar, Ok. Causes and penalties of snake venom variation. Developments Pharmacol. Sci. 41, 570–581 (2020).
Durban, J. et al. Built-in venomics and venom gland transcriptome evaluation of juvenile and grownup Mexican rattlesnakes Crotalus simus, C. tzabcan, and C. culminatus revealed miRNA-modulated ontogenetic shifts. J. Proteome Res. 16, 3370–3390 (2017).
Pla, D. et al. Phylovenomics of Daboia russelii throughout the Indian subcontinent. Bioactivities and comparative in vivo neutralization and in vitro third-generation antivenomics of antivenoms towards venoms from India, Bangladesh and Sri Lanka. J. Proteom. 207, 103443 (2019).
Senji Laxme, R. R. et al. Past the ‘huge 4’: venom profiling of the medically vital but uncared for Indian snakes reveals disturbing antivenom deficiencies. PLoS Negl. Trop. Dis. 13, e0007899 (2019).
Chanda, A., Kalita, B., Patra, A., Senevirathne, W. D. S. T. & Mukherjee, A. Ok. Proteomic evaluation and antivenomics examine of Western India Naja naja venom: correlation between venom composition and scientific manifestations of cobra chunk on this area. Professional Rev. Proteom. 16, 171–184 (2018).
Tasoulis, T., Pukala, T. L. & Isbister, G. Ok. Investigating toxin range and abundance in snake venom proteomes. Entrance. Pharmacol. (2022). A assessment of the proteomic strategies used to separate and quantify snake venom toxins, evaluating their deserves and limitations.
Editorial. Snake-bite envenoming: a precedence uncared for tropical illness. Lancet 390, 2 (2017).
Gutierrez, J. M. et al. Snakebite envenoming. Nat. Rev. Dis. Primers 3, 17063 (2017). A assessment on the pathophysiology and therapy of snakebite envenoming.
Williams, D. The International Snake Chew Initiative: an antidote for snake chunk. Lancet 375, 89–91 (2010).
Kasturiratne, A. et al. The worldwide burden of snakebite: a literature evaluation and modelling primarily based on regional estimates of envenoming and deaths. PLoS Med. 5, 1591–1604 (2008).
McDermott, A. Venom again in vogue as a wellspring for drug candidates. Proc. Natl Acad. Sci. USA 117, 10100–10104 (2020).
Bordon, Ok. et al. From animal poisons and venoms to medicines: achievements, challenges and views in drug discovery. Entrance. Pharmacol. 11, 1132 (2020).
Almeida, J. R. R. et al. Snake venom peptides and low mass proteins: molecular instruments and therapeutic brokers. Curr. Med. Chem. 24, 3254–3282 (2017).
Fry, B. G. From genome to “venome”: molecular origin and evolution of the snake venom proteome inferred from phylogenetic evaluation of toxin sequences and associated physique proteins. Genome Res. 15, 403–420 (2005).
Ojeda, P. G. et al. Computational research of snake venom toxins. Toxins 10, 8 (2018).
Calvete, J. J., Sanz, L., Angulo, Y., Lomonte, B. & Gutiérrez, J. M. Venoms, venomics, antivenomics. FEBS Lett. 583, 1736–1743 (2009).
Modahl, C. M., Brahma, R. Ok., Koh, C. Y., Shioi, N. & Kini, R. M. Omics applied sciences for profiling toxin range and evolution in snake venom: impacts on the invention of therapeutic and diagnostic brokers. Annu. Rev. Anim. Biosci. 8, 91–116 (2020).
The Uniprot Consortium. UniProt: the common protein knowledgebase in 2021. Nucleic Acids Res. 49, 480–489 (2021).
Simoes-Silva, R. et al. Snake venom, a pure library of latest potential therapeutic molecules: challenges and present views. Curr. Pharm. Biotechnol. 19, 308–335 (2018).
Calvete, J. J. Subsequent-generation snake venomics: protein-locus decision by venom proteome decomplexation. Professional Rev. Proteom. 11, 315–329 (2014).
Brahma, R. Ok., McCleary, R. J. R., Kini, R. M. & Doley, R. Venom gland transcriptomics for figuring out, cataloging, and characterizing venom proteins in snakes. Toxicon 93, 1–10 (2015).
Liu, L. Comparability of next-generation sequencing methods. J. Biomed. Biotechnol. 2012, 251364 (2012).
Gutiérrez, J. M. & Lomonte, B. Phospholipases A2: unveiling the secrets and techniques of a functionally versatile group of snake venom toxins. Toxicon 62, 27–39 (2013). A assessment of the construction and performance of the central PLA2 toxin household.
Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V. & Kokotos, G. Phospholipase A2 enzymes: bodily construction, organic operate, illness implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 111, 6130–6185 (2011).
Kang, T. S. et al. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J. 278, 4544–4576 (2011). A paper specializing in the construction and response mechanisms of essentially the most distinguished snake venom enzymatic toxins.
Schaloske, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761, 1246–59 (2006).
Ferraz, C. R. et al. Multifunctional toxins in snake venoms and therapeutic implications: from ache to hemorrhage and necrosis. Entrance. Ecol. Evol. 7, 218 (2019).
Kini, R. M. & Koh, C. Y. Snake venom three-finger toxins and their potential in drug improvement concentrating on cardiovascular ailments. Biochem. Pharmacol. 181, 114105 (2020). A assessment of the household of 3FTxs and their potential medicinal purposes for cardiovascular ailments.
Fry, B. G. et al. Molecular evolution and phylogeny of elapid snake venom three-finger toxins. J. Mol. Evol. 57, 110–129 (2003).
Kini, R. M. & Doley, R. Construction, operate and evolution of three-finger toxins: mini proteins with a number of targets. Toxicon 56, 855–867 (2010).
Olaoba, O. T., Karina dos Santos, P., Selistre-de-Araujo, H. S. & Ferreira de Souza, D. H. Snake venom metalloproteinases (SVMPs): a construction–operate replace. Toxicon X 7, 100052 (2020). A assessment of the big and sophisticated household of SVMP toxins.
Gutiérrez, J. M., Escalante, T., Rucavado, A. & Herrera, C. Hemorrhage brought on by snake venom metalloproteinases: a journey of discovery and understanding. Toxins 8, 93 (2016).
Takeda, S. ADAM and ADAMTS household proteins and snake venom metalloproteinases: a structural overview. Toxins 8, 155 (2016).
Ullah, A. et al. Thrombin-like enzymes from snake venom: structural characterization and mechanism of motion. Int. J. Biol. Macromol. 114, 788–811 (2018).
Hiu, J. J. & Yap, M. Ok. Ok. Cytotoxicity of snake venom enzymatic toxins: phospholipase A(2) and l-amino acid oxidase. Biochem. Soc. Trans. 48, 719–731 (2020).
Tan, Ok. Ok., Bay, B. H. & Gopalakrishnakone, P. l-amino acid oxidase from snake venom and its anticancer potential. Toxicon 144, 7–13 (2018).
Paloschi, M. V. An replace on potential molecular mechanisms underlying the actions of snake venom l-amino acid oxidases (LAAOs). Curr. Med. Chem. 25, 2520–2530 (2018).
Ullah, A. Construction–operate research and mechanism of motion of snake venom l-amino acid oxidases. Entrance. Pharmacol. 11, 110 (2020).
Inagaki, H. in Snake Venoms (eds Gopalakrishnakone, P., Inagaki, H., Vogel, C.-V., Mukherjee, A. Ok. & Rashed Rahmy, T.) (Springer, 2017).
Markland, F. S. & Swenson, S. Snake venom metalloproteinases. Toxicon 62, 3–18 (2013).
Serrano, S. M. & Maroun, R. C. Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved. Toxicon 45, 1115–1132 (2005).
Serrano, S. M. The lengthy highway of analysis on snake venom serine proteinases. Toxicon 62, 19–26 (2013).
Arlinghaus, F. T. & Eble, J. A. C-type lectin-like proteins from snake venoms. Toxicon 60, 512–519 (2012).
Morita, T. Buildings and features of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating actions. Toxicon 45, 1099–1114 (2005).
Lu, Q., Navdaev, A., Clemetson, J. M. & Clemetson, Ok. J. Snake venom C-type lectins interacting with platelet receptors. Construction–operate relationships and results on haemostasis. Toxicon 45, 1089–1098 (2005).
Vink, S. Natriuretic peptide drug leads from snake venom. Toxicon 59, 434–445 (2012).
Sridharan, S., Kini, R. M. & Richards, A. M. Venom natriuretic peptides information the design of coronary heart failure therapeutics. Pharmacol. Res. 155, 104687 (2020). This assessment examines the construction–operate relationships of venom natriuretic peptides, and discusses peptide engineering methods for creating therapeutic natriuretic peptide analogues.
Munawar, A. Snake venom peptides: instruments of biodiscovery. Toxins 10, 474 (2018).
Laustsen, A. H., Lomonte, B., Lohse, B., Fernández, J. & Gutiérrez, J. M. Unveiling the character of black mamba (Dendroaspis polylepis) venom by venomics and antivenom immunoprofiling: identification of key toxin targets for antivenom improvement. J. Proteom. 119, 126–142 (2015).
Damm, M., Hempel, B. F., Nalbantsoy, A. & Süssmuth, R. D. Complete snake venomics of the Okinawa Habu pit viper, Protobothrops flavoviridis, by complementary mass spectrometry-guided approaches. Molecules 23, 1893 (2018).
Coronado, M. A. et al. Construction of the polypeptide crotamine from the Brazilian rattlesnake Crotalus durissus terrificus. Acta Crystallogr. D 69, 1958–1964 (2013).
Falcao, C. B. & Radis-Baptista, G. Crotamine and crotalicidin, membrane lively peptides from Crotalus durissus terrificus rattlesnake venom, and their structurally-minimized fragments for purposes in drugs and biotechnology. Peptides 126, 170234 (2020).
Slotta, Ok. H. & Fraenkel-Conrat, H. Two lively proteins from rattlesnake venom. Nature 13, 213–213 (1938).
Berg, O. G., Gelb, M. H., Tsai, M. D. & Jain, M. Ok. Interfacial enzymology: the secreted phospholipase A(2)-paradigm. Chem. Rev. 101, 2613–54 (2001).
Tsai, Y. C., Yu, B. Z., Wang, Y. Z., Chen, J. & Jain, M. Ok. Desolvation map of the i-face of phospholipase A2. Biochim. Biophys. Acta 1758, 653–665 (2006).
Bahnson, B. J. Construction, operate and interfacial allosterism in phospholipase A2: perception from the anion-assisted dimer. Arch. Biochem. Biophys. 433, 96–106 (2005).
Scott, D. L. et al. Interfacial catalysis: the mechanism of phospholipase A2. Science 250, 1541–1546 (1990).
Sérgio, S., Ramos, M. J., Lim, C. & Fernandes, P. A. Relationship between enzyme/substrate properties and enzyme effectivity in hydrolases. ACS Catal. 5, 5877–5887 (2015).
Sousa, S. F. et al. Activation free power, substrate binding free power, and enzyme effectivity fall in a really slender vary of values for many enzymes. ACS Catal. 10, 8444–8453 (2020).
Resende, L. M. et al. Structural, enzymatic and pharmacological profiles of AplTX-II — a fundamental sPLA2 (D49) remoted from the Agkistrodon piscivorus leucostoma snake venom. Int. J. Biol. Macromol. 175, 572–585 (2021).
Lomonte, B. & Rangel, J. Snake venom Lys49 myotoxins: from phospholipases A(2) to non-enzymatic membrane disruptors. Toxicon 60, 520–30 (2012).
Fernández, J. et al. Muscle phospholipid hydrolysis by Bothrops asper Asp49 and Lys49 phospholipase A2 myotoxins — distinct mechanisms of motion. FEBS J. 280, 3878–3886 (2013).
Almeida, J. R. et al. CoaTx-II, a brand new dimeric Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom with bactericidal potential: insights into its construction and organic roles. Toxicon 120, 147–58 (2016).
Almeida, J. R. et al. Harnessing snake venom phospholipases A(2) to novel approaches for overcoming antibiotic resistance. Drug Dev. Res. 80, 68–85 (2019).
Almeida, J. R. et al. A novel artificial peptide impressed on Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom lively towards multidrug-resistant scientific isolates. Eur. J. Med. Chem. 149, 248–256 (2018).
Kwong, P. D., McDonald, N. Q., Sigler, P. B. & Hendrickson, W. A. Construction of β2-bungarotoxin — potassium channel binding by kunitz modules and focused phospholipase motion. Construction 3, 1109–1119 (1995).
Rowan, E. G. What does β-bungarotoxin do on the neuromuscular junction? Toxicon 39, 107–118 (2001).
Doley, R. & Kini, R. M. Protein complexes in snake venom. Cell. Mol. Life Sci. 66, 2851–2871 (2009).
Kini, R. M. & Koh, C. Y. Metalloproteases affecting blood coagulation, fibrinolysis and platelet aggregation from snake venoms: definition and nomenclature of interplay websites. Toxins 8, 284 (2016).
Sanchez, E. F., Flores-Ortiz, R. J., Alvarenga, V. G. & Eble, J. A. Direct fibrinolytic snake venom metalloproteinases affecting hemostasis: structural, biochemical options and therapeutic potential. Toxins 9, 392 (2017).
Bledzka, Ok., Smyth, S. S. & Plow, E. F. Integrin αIIbβ3 from discovery to efficacious therapeutic goal. Circ. Res. 112, 1189–1200 (2013).
Takeda, S., Igarashi, T. & Mori, H. Crystal construction of RVV-X: an instance of evolutionary acquire of specificity by ADAM proteinases. FEBS Lett. 581, 5859–5864 (2007).
Lingott, T., Schleberger, C., Gutiérrez, J. M. & Merfort, I. Excessive-resolution crystal construction of the snake venom metalloproteinase BaP1 complexed with a peptidomimetic: Perception into inhibitor binding. Biochemistry 48, 6166–6174 (2009).
Akao, P. Ok. et al. Structural research of BmooMPα-I, a non-hemorrhagic metalloproteinase from Bothrops moojeni venom. Toxicon 55, 361–368 (2010).
Boldrini-França, J. et al. Past hemostasis: a snake venom serine protease with potassium channel blocking and potential antitumor actions. Sci. Rep. 10, 4476 (2020).
Mackessy, S. P. in Toxins and Hemostasis (eds Kini, R., Clemetson, Ok., Markland, F., McLane, M. & Morita, T.) 519–557 (Springer, 2010).
Vaiyapuri, S., Thiyagarajan, N., Hutchinson, E. G. & Gibbins, J. M. Sequence and phylogenetic evaluation of viper venom serine proteases. Bioinformation 8, 763–772 2012).
Kurtović, T. et al. VaSP1, catalytically lively serine proteinase from Vipera ammodytes ammodytes venom with unconventional lively website triad. Toxicon 77, 93–104 (2014).
Sousa, S. F. et al. Utility of quantum mechanics/molecular mechanics strategies within the examine of enzymatic response mechanisms. Wiley Interdisc. Rev. Mol. Sci. 7, 1281 (2017). A assessment of the computational strategies getting used to elucidate the snake venom enzymatic reactivity.
Chung, L. W. et al. The ONIOM technique and its purposes. Chem. Rev. 115, 5678–5796 (2015).
Amaro, R. E. & Mulholland, A. J. Multiscale strategies in drug design bridge chemical and organic complexity within the seek for cures. Nat. Rev. Chem. 2, 148 (2018).
Himo, F. Latest developments in quantum chemical modeling of enzymatic reactions. J. Am. Chem. Soc. 139, 6780–6786 (2017).
Estevão-Costa, M. I., Sanz-Soler, R., Johanningmeier, B. & Eble, J. A. Snake venom parts in drugs: from the symbolic rod of Asclepius to tangible medical analysis and utility. Int. J. Biochem. Cell Biol. 104, 94–113 (2018). This assessment describes the appliance of snake venoms in drug discovery.
Marsh, N. A. Diagnostic makes use of of snake venom. Haemostasis 31, 211–217 (2001).
Francischetti, I. M. B. & Gil, M. R. in Transfusion Drugs and Hemostasis (eds Shaz, B. H., Hillyer, C. D. & Reyes Gil, M.) 969–975 (Elsevier, 2019).
Schmidtko, A., Lötsch, J., Freynhagen, R. & Geisslinger, G. Ziconotide for therapy of extreme persistent ache. Lancet 375, 1569–1577 (2010).
Miljanich, G. P. Ziconotide: neuronal calcium channel blocker for treating extreme persistent ache. Curr. Med. Chem. 11, 3029–3040 (2004).
Rocha, E. S. M., Beraldo, W. T. & Rosenfeld, G. Bradykinin, a hypotensive and easy muscle stimulating issue launched from plasma globulin by snake venoms and by trypsin. Am. J. Physiol. 156, 261–273 (1949).
Ferreira, S. H. A bradykinin-potentiating issue (BPF) current within the venom of Bothrops jararaca. Br. J. Pharmacol. Chemother. 24, 163–169 (1965).
Ferreira, S. H., Bartelt, D. C. & Greene, L. J. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9, 2583–2593 (1970).
McCleary, R. J. R. & Kini, R. M. Non-enzymatic proteins from snake venoms: a gold mine of pharmacological instruments and drug leads. Toxicon 62, 56–74 (2013).
Ferreira, S. H., Greene, L. J., Alabaster, V. A., Bakhle, Y. S. & Vane, J. R. Exercise of assorted fractions of bradykinin potentiating issue towards angiotensin-I changing enzyme. Nature 225, 379–380 (1970).
Cushman, D. W. & Ondetti, M. A. Historical past of the design of captopril and associated inhibitors of angiotensin changing enzyme. Hypertension 17, 589–592 (1991).
Bryan, J. From snake venom to ACE inhibitor — the invention and rise of captopril. Pharm. J. 282, 455–456 (2009).
Patchett, A. A. The chemistry of enalapril. Br. J. Clin. Pharmacol. 18, 201–207 (1984).
Acharya, Ok. R., Sturrock, E. D., Riordan, J. F. & Ehlers, M. R. W. ACE revisited: a brand new goal for structure-based drug design. Nat. Rev. Drug Discov. 2, 891–902 (2003).
Acharya, G., Wang, W., Vavilala, D. T., Mukherji, M. & Lee, C. H. in Superior Drug Supply (eds Mitra, A. Ok., Lee, C. H. & Cheng, Ok.) 341–364 (Wiley, 2014).
Lazarovici, P., Marcinkiewicz, C. & Lelkes, P. I. From snake venom’s disintegrins and C-type lectins to anti-platelet medicine. Toxins 11, 303 (2019).
Topol, E. J., Byzova, T. V. & Plow, E. F. Platelet GPIIb-IIIa blockers. Lancet 353, 227–231 (1999).
Lang, S. H. et al. Remedy with tirofiban for acute coronary syndrome (ACS): a scientific assessment and community evaluation. Curr. Med. Res. Opin. 28, 351–370 (2012).
Barrett, J. S. et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective nonpeptide platelet glycoprotein-IIb/IIIa receptor antagonist, in wholesome males. Clin. Pharmacol. Ther. 56, 377–388 (1994).
Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A. & Polokoff, M. A. Echistatin — a potent platelet-aggregation inhibitor from the venom of the viper Echis carinatus. J. Biol. Chem. 263, 19827–19832 (1988).
Hartman, G. D. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640–4642 (1992).
Van Drie, J. H. Laptop-aided drug design: the subsequent 20 years. J. Comput. Aided Mol. Des. 21, 591–601 (2007).
Scarborough, R. M. et al. Design of potent and particular integrin antagonists — peptide antagonists with excessive specificity for glycoprotein-IIb–IIIa. J. Biol. Chem. 268, 1066–1073 (1993).
Scarborough, R. M. et al. Barbourin — a GPIIb–IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem. 266, 9359–9362 (1991).
Scarborough, R. M. Improvement of eptifibatide. Am. Coronary heart J. 138, 1093–1104 (1999).
O’Shea, J. C. & Tcheng, J. E. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Professional Opin. Pharmacother. 3, 1199–1210 (2002).
Masuda, H. Batroxobin accelerated tissue restore by way of neutrophil extracellular lure regulation and defibrinogenation in a murine ischemic hindlimb mannequin. PLoS ONE 14, e0220898 (2019).
Vu, T. T. Batroxobin binds fibrin with greater affinity and promotes clot growth to a better extent than thrombin. J. Biol. Chem. 288, 16862–16871 (2013).
Waheed, H., Moin, S. F. & Choudhary, M. I. Snake venom: from lethal toxins to life-saving therapeutics. Curr. Med. Chem. 24, 1874–1891 (2017).
Gazerani, P. & Cairns, B. E. Venom-based biotoxins as potential analgesics. Professional Rev. Neurother. 14, 1261–1274 (2014).
Lin, F., Reid, P. F. & Qin, Z.-H. Cobrotoxin might be an efficient therapeutic for COVID-19. Acta Pharmacol. Sin. 41, 1258–1260 (2020).
Pérez-Peinado, C. et al. Hitchhiking with nature: snake venom peptides to battle most cancers and superbugs. Toxins 12, 255 (2020). This assessment describes the appliance of snake venoms to deal with most cancers and an infection by antibiotic-resistant microorganisms.
Li, B. X. et al. In vitro evaluation and part I randomized scientific trial of anfibatide, a snake-venom-derived anti-thrombotic agent concentrating on human platelet GPIbα. Sci. Rep. 11, 11663 (2021).
Gao, Y. et al. Crystal construction of agkisacucetin, a GPIb-binding snake C-type lectin that inhibits platelet adhesion and aggregation. Proteins 80, 1707–1711 (2012).
Jackson, S. P. The rising complexity of platelet aggregation. Blood 109, 5087–5095 (2007).
Guo, Y. et al. Balancing the expression and manufacturing of a heterodimeric protein: recombinant agkisacutacin as a novel antithrombotic drug candidate. Sci. Rep. 5, 11730 (2015).
Tasima, L. J. et al. Crotamine in Crotalus durissus: distribution in line with subspecies and geographic origin, in captivity or nature. J. Venom. Anim. Toxins Incl. Trop. Dis. 26, 20190053 (2020).
Moreira, L. A. et al. Acute toxicity, antinociceptive, and anti inflammatory actions of the orally administered crotamine in mice. Naunyn Schmiedebergs Arch. Pharmacol. 394, 1703–1711 (2021).
Nicastro, G. et al. Answer construction of crotamine, a Na+ channel affecting toxin from Crotalus durissus terrificus venom. Eur. J. Biochem. 270, 1969–1979 (2003).
Kerkis, A. et al. Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus. FASEB J. 18, 1407–1409 (2004).
Hayashi, M. A. F. et al. Cytotoxic results of crotamine are mediated by lysosomal membrane permeabilization. Toxicon 52, 508–517 (2008).
Kerkis, A., Hayashi, M. A. F., Yamane, T. & Kerkis, I. Properties of cell penetrating peptides (CPPs). IUBMB Life 58, 7–13 (2006).
Pereira, A. et al. Crotamine toxicity and efficacy in mouse fashions of melanoma. Professional Opin. Investig. Medication 20, 1189–1200 (2011).
Campeiro, J. D. et al. Oral therapy with a rattlesnake native polypeptide crotamine effectively inhibits the tumor progress with no potential toxicity for the host animal and with suggestive constructive results on animal metabolic profile. Amino Acids 50, 267–278 (2018). This examine demonstrates the promising antitumoral exercise of crotamine by oral administration.
Mancin, A. C. et al. The analgesic exercise of crotamine, a neurotoxin from Crotalus durissus terrificus (South American rattlesnake) venom: a biochemical and pharmacological examine. Toxicon 36, 1927–37 (1998).
de Carvalho Porta, L. et al. Biophysical and pharmacological characterization of a full-length artificial analog of the antitumor polypeptide crotamine. J. Mol. Med. 98, 1561–1571 (2020).
Mambelli-Lisboa, N. C., Sciani, J. M., Silva, A. R. B. P. D. & Kerkis, I. Co-localization of crotamine with inside membranes and accentuated accumulation in tumor cells. Molecules 23, 968 (2018).
Park, J. Y. et al. Antinociceptive and anti inflammatory results of recombinant crotamine in mouse fashions of ache. Toxins 13, 707 (2021). An in vivo examine of the antinociceptive and anti inflammatory exercise of crotamine.
Schweitz, H., Vigne, P., Moinier, D., Frelin, C. & Lazdunski, M. A brand new member of the natriuretic peptide household is current within the venom of the inexperienced mamba (Dendroaspis angusticeps). J. Biol. Chem. 267, 13928–13932 (1992).
Volpe, M., Rubattu, S. & Burnett, J. Natriuretic peptides in cardiovascular ailments: present use and views. Eur. Coronary heart J. 35, 419–425 (2014).
O’Connor, C. M. M. et al. Impact of nesiritide in sufferers with acute decompensated coronary heart failure. N. Engl. J. Med. 365, 32–43 (2011).
Matsue, Y. et al. Carperitide is related to elevated in-hospital mortality in acute coronary heart failure: a propensity score-matched evaluation. J. Card. Fail. 21, 859–864 (2015).
Ichiki, T., Dzhoyashvili, N. & Burnett, J. C. Jr Natriuretic peptide primarily based therapeutics for coronary heart failure: cenderitide. A novel first-in-class designer natriuretic peptide. Int. J. Cardiol. 281, 166–171 (2019).
Kawakami, R. et al. A human examine to guage security, tolerability, and cyclic GMP activating properties of cenderitide in topics with secure persistent coronary heart failure. Clin. Pharmacol. Ther. 104, 546–552 (2018).
Diochot, S. et al. Black mamba venom peptides goal acid-sensing ion channels to abolish ache. Nature 490, 552–557 (2012). This paper studies the invention of a black mamba 3FTx that targets acid-sensing ion channels with potent analgesic exercise.
Yoder, N., Yoshioka, C. & Gouaux, E. Gating mechanisms of acid-sensing ion channels. Nature 555, 397–401 (2018).
Wemmie, J. A., Taugher, R. J. & Kreple, C. J. Acid-sensing ion channels in ache and illness. Nat. Rev. Neurosci. 14, 461–471 (2013).
Schroeder, C. I. et al. Chemical synthesis, 3D construction, and ASIC binding website of the toxin mambalgin-2. Angew. Chem. Int. Ed. 53, 1017–1020 (2014).
Mourier, G. et al. Mambalgin-1 pain-relieving peptide, stepwise solid-phase synthesis, crystal construction, and purposeful area for acid-sensing ion channel 1a Inhibition. J. Biol. Chem. 291, 2616–2629 (2015).
Diochot, S. et al. Analgesic results of mambalgin peptide inhibitors of acid-sensing ion channels in inflammatory and neuropathic ache. Ache 157, 552–559 (2016).
Verkest, C. et al. Results of systemic inhibitors of acid-sensing ion channels 1 (ASIC1) towards acute and persistent mechanical allodynia in a rodent mannequin of migraine. Br. J. Pharmacol. 175, 4154–4166 (2018).
Solar, D. M. et al. Structural insights into human acid-sensing ion channel 1a inhibition by snake toxin mambalgin1. eLife 9, 57096 (2020). This paper studies structural particulars of the working mechanism of the analgesic mambalgin-1 in blocking the acid-sensing ion channel 1a.
Salinas, M. et al. Mambalgin-1 pain-relieving peptide locks the hinge between α4 and α5 helices to inhibit rat acid-sensing ion channel 1a. Neuropharmacology 185, 108453 (2021).
Yacoub, T. Antimicrobials from venomous animals: an outline. Molecules 25, 2402 (2020).
Siniavin, A. E. et al. Snake venom phospholipase A2s exhibit sturdy virucidal exercise towards SARS-CoV-2 and inhibit the viral spike glycoprotein interplay with ACE2. Cell Mol. Life Sci. 78, 7777–7794 (2021).
Santos-Filho, N. A. et al. Antibacterial exercise of the non-cytotoxic peptide (p-BthTX-I)2 and its serum degradation product towards multidrug-resistant micro organism. Molecules 22, 1898 (2017).
Freire, M. C. L. C. et al. Non-toxic dimeric peptides derived from the bothropstoxin-I are potent SARS-CoV-2 and papain-like protease inhibitors. Molecules 26, 4896 (2021). A report of snake venom peptides with antiviral exercise in direction of SARS-CoV-2.
Domling, A. & Gao, L. Chemistry and biology of SARS-CoV-2. Chem 6, 1283–1295 (2020).
Yang, J. et al. Freely accessible chemical database sources of compounds for in silico drug discovery. Curr. Med. Chem. 26, 7581–7597 (2019).
Mendez, D. et al. ChEMBL: in direction of direct deposition of bioassay knowledge. Nucleic Acids Res. 47, 930–940 (2019).
Sterling, T. & Irwin, J. J. ZINC 15-ligand discovery for everybody. J. Chem. Inf. Mannequin. 55, 2324–2337 (2015).
van Hilten, N. et al. Digital compound libraries in computer-assisted drug discovery. J. Chem. Inf. Mannequin. 59, 644–651 (2019).
Schneider, G. Automating drug discovery. Nat. Rev. Drug Discov. 17, 97–113 (2018).
Warkentin, T. E., Greinacher, A. & Koster, A. Bivalirudin. Thromb. Haemost. 99, 830–9 (2008).
Barnett, A. Exenatide. Professional Opin. Pharmacother. 8, 2593–2608 (2007).
King, G. F. in Venoms to Medication: Venom as a Supply for the Improvement of Human Therapeutics (ed. King, G. F.) 37–79 (Royal Society of Chemistry, 2015).
Kini, R. M. Toxins in thrombosis and haemostasis: potential past creativeness. J. Thromb. Haemost. 9, 195–208 (2011).
Santos, R. et al. A complete map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017).
Kini, R. M. & Evans, H. J. A mannequin to elucidate the pharmacological results of snake venom phospholipases A2. Toxicon 27, 613–35 (1989).
Kini, R. M. Pleasure forward: construction, operate and mechanism of snake venom phospholipase A2 enzymes. Toxicon 42, 827–840 (2003).
Croll, T. I., Sammito, M. D., Kryshtafovych, A. & Learn, R. J. Analysis of template-based modeling in CASP13. Proteins Struct. Funct. Bioinform. 87, 1113–1127 (2019).
Alford, R. F. et al. The Rosetta all-atom power operate for macromolecular modeling and design. J. Chem. Concept Comput. 13, 3031–3048 (2017).
Das, R. & Baker, D. Macromolecular modeling with Rosetta. Annu. Rev. Biochem. 77, 363–382 (2008).
Wang, Y., Virtanen, J., Xue, Z. & Zhang, Y. I-TASSER-MR: automated molecular alternative for distant-homology proteins utilizing iterative fragment meeting and progressive sequence truncation. Nucleic Acids Res. 45, 429–434 (2017).
Webb, B. & Sali, A. Comparative protein construction modeling utilizing MODELLER. Curr. Protoc. Bioinformatics 54, 5.6.1–5.6.37 (2020).
Jumper, J. et al. Extremely correct protein construction prediction with AlphaFold. Nature 596, 583–589 (2021).
Lensink, M. F., Nadzirin, N., Velankar, S. & Wodak, S. J. Modeling protein–protein, protein–peptide, and protein–oligosaccharide complexes: CAPRI. Proteins 88, 916–938 (2020).
Moreira, I. S., Fernandes, P. A. & Ramos, M. J. Protein–protein docking coping with the unknown. J. Comput. Chem. 31, 317–342 (2010).
Simões, I. C. M. et al. Properties that rank protein–protein docking poses with excessive accuracy. Phys. Chem. Chem. Phys. 20, 20927–20942 (2018). A promising computational technique to foretell toxin–goal complexation buildings.
Moreira, I. S., Martins, J. M., Coimbra, J. T. S., Ramos, M. J. & Fernandes, P. A. A brand new scoring operate for protein–protein docking that identifies native buildings with unprecedented accuracy. Phys. Chem. Chem. Phys. 17, 2378–2387 (2015).
Quignot, C. et al. InterEvDock2: an expanded server for protein docking utilizing evolutionary and organic data from homology fashions and multimeric inputs. Nucleic Acids Res. 46, 408–416 (2018).
Kozakov, D. et al. The ClusPro net server for protein-protein docking. Nat. Protoc. 12, 255–278 (2017).
Park, T., Baek, M., Lee, H. & Seok, C. GalaxyTongDock: symmetric and uneven ab initio protein–protein docking net server with improved power parameters. J. Comput. Chem. 40, 2413–2417 (2019).
Zundert, G. C. P. et al. The HADDOCK2.2 net server: user-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720–725 (2016).
Moreira, I. S., Fernandes, P. A. & Ramos, M. J. Scorching spots — a assessment of the protein–protein interface determinant amino-acid residues. Proteins Struct. Funct. Bioinform. 68, 803–812 (2007).
Martins, S. A. et al. Computational alanine scanning mutagenesis: MM-PBSA vs TI. J. Chem. Concept Comput. 9, 1311–1319 (2013).
Simões, I. C. M., Costa, I. P. D., Coimbra, J. T. S., Ramos, M. J. & Fernandes, P. A. New parameters for greater accuracy within the computation of binding free power variations upon alanine scanning mutagenesis on protein–protein interfaces. J. Chem. Inf. Mannequin. 57, 60–72 (2017). An correct computational technique to establish toxin–goal binding areas and binding epitopes.
Geng, C., Xue, L. C., Roel-Touris, J. & Bonvin, A. M. J. J. Discovering the ΔΔG spot: are predictors of binding affinity modifications upon mutations in protein–protein interactions prepared for it? Wiley Interdiscip. Rev. Mol. Sci. 9, 1410 (2019).
Barlow, Ok. A. et al. Flex ddG: Rosetta ensemble-based estimation of modifications in protein–protein binding affinity upon mutation. J. Phys. Chem. B 122, 5389–5399 (2018).
Kortemme, T. & Baker, D. A easy bodily mannequin for binding power scorching spots in protein–protein complexes. Proc. Natl Acad. Sci. USA 99, 14116–21 (2002).
Sribar, J. et al. The neurotoxic secreted phospholipase A2 from the Vipera a. ammodytes venom targets cytochrome c oxidase in neuronal mitochondria. Sci. Rep. 9, 283 (2019).
Meenakshisundaram, R., Sweni, S. & Thirumalaikolundusubramanian, P. Speculation of snake and bug venoms towards human immunodeficiency virus: a assessment. AIDS Res. Ther. 6, 25 (2009).
Fenard, D. et al. Secreted phospholipases A2, a brand new class of HIV inhibitors that block virus entry into host cells. J. Clin. Make investments. 104, 611–618 (1999).
Muller, V. D. M. et al. Crotoxin and phospholipases A2 from Crotalus durissus terrificus confirmed antiviral exercise towards dengue and yellow fever viruses. Toxicon 59, 507–15 (2012).
Ahmed, N. Ok., Tennant, Ok. D., Markland, F. S. & LACZ, J. P. Biochemical traits of fibrolase, a fibrinolytic protease from snake venom. Haemostasis 20, 147–154 (1990).
Boldrini-Franca, J., Pinheiro-Junior, E. L. & Arantes, E. C. Purposeful and organic insights of rCollinein-1, a recombinant serine protease from Crotalus durissus collilineatus. J. Venom. Anim. Toxins Incl. Trop. Dis. 25, 147118 (2019).
Funk, C., Gmür, J., Herold, R. & Straub, P. W. Reptilase-R — a brand new reagent in blood coagulation. Br. J. Haematol. 21, 43–52 (1971).
Graziano, F. et al. Autologous fibrin sealant (Vivostat(R)) within the neurosurgical observe. Half I: intracranial surgical process. Surg. Neurol. Int. 6, 77 (2015).
Graziano, F., Maugeri, R., Basile, L., Meccio, F. & Iacopino, D. G. Aulogous fibrin sealant (Vivostat(R)) within the neurosurgical observe. Half II: vertebro-spinal procedures. Surg. Neurol. Int. 7, 77–82 (2016).
Koivula, Ok., Rondinelli, S. & Nasman, J. The three-finger toxin MTα is a selective α2B-adrenoceptor antagonist. Toxicon 56, 440–447 (2010).
Barnwal, B. et al. Ringhalexin from Hemachatus haemachatus: a novel inhibitor of extrinsic tenase complicated. Sci. Rep. 6, 25935 (2016).
Banerjee, Y. et al. Biophysical characterization of anticoagulant hemextin AB complicated from the venom of snake Hemachatus haemachatus. Biophys. J. 93, 3963–76 (2007).
Chanda, C., Sarkar, A., Sistla, S. & Chakrabarty, D. Anti-platelet exercise of a three-finger toxin (3FTx) from Indian monocled cobra (Naja kaouthia) venom. Biochem. Biophys. Res. Commun. 441, 550–554 (2013).
Fernandez-Gomez, R. et al. Progress inhibition of Trypanosoma cruzi and Leishmania donovani infantum by totally different snake venoms — preliminary identification of proteins from Cerastes cerastes venom which work together with the parasites. Toxicon 32, 875–882 (1994).
Costa Torres, A. F. et al. Antibacterial and antiparasitic results of Bothrops marajoensis venom and its fractions: phospholipase A2 and l-amino acid oxidase. Toxicon 55, 795–804 (2010).
Sakurai, Y. et al. Anticoagulant exercise of M-LAO, l-amino acid oxidase purified from Agkistrodon halys blomhoffii, by selective inhibition of issue IX. Biochim. Biophys. Acta 1649, 51–57 (2003).
Adade, C. M. et al. Crovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising exercise towards trypanosomes and Leishmania. PLoS Negl. Trop. Dis. 8, 3252 (2014).
Badari, J. C., Díaz-Roa, A., Rocha, M. M. T., Mendonça, R. Z. & Silva Junior, P. I. D. Patagonin-CRISP: antimicrobial exercise and supply of antimicrobial molecules in Duvernoy’s gland secretion (Philodryas patagoniensis snake). Entrance. Pharmacol. 11, 586705 (2021).
Tadokoro, T., Modahl, C. M., Maenaka, Ok. & Aoki-Shioi, N. Cysteine-rich secretory proteins (CRISPs) from venomous snakes: an outline of the purposeful range in a big and underappreciated superfamily. Toxins 12, 175 (2020).
Assafim, M. et al. Exploiting the antithrombotic impact of the (professional)thrombin inhibitor bothrojaracin. Toxicon 119, 46–51 (2016).
Shen, D.-Ok. et al. Ca2+-induced binding of anticoagulation issue II from the venom of Agkistrodon acutus with issue IX. Biopolymers 97, 818–824 (2012).
Zhang, Y. et al. Anticoagulation issue I, a snaclec (snake C-type lectin) from Agkistrodon acutus venom binds to FIX in addition to FX: Ca2+ induced binding knowledge. Toxicon 59, 718–723 (2012).
Rabelo, L. F. G. et al. Alternagin-C, a disintegrin-like protein from Bothrops alternatus venom, attenuates irritation and angiogenesis and stimulates collagen deposition of sponge-induced fibrovascular tissue in mice. Int. J. Biol. Macromol. 140, 653–660 (2019).
Gilchrist, I. C. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: concentrate on the pharmacokinetic–pharmacodynamic relationships of eptifibatide. Clin. Pharmacokinet. 42, 703–720 (2003).
Lucena, S. E. et al. Anti-invasive and anti-adhesive actions of a recombinant disintegrin, r-viridistatin 2, derived from the Prairie rattlesnake (Crotalus viridis viridis). Toxicon 60, 31–9 (2012).
Kuo, Y. J., Chung, C. H. & Huang, T. F. From discovery of snake venom disintegrins to a safer therapeutic antithrombotic agent. Toxins 11, 372 (2019).
Cesar, P. H. S., Braga, M. A., Trento, M. V. C., Menaldo, D. L. & Marcussi, S. Snake venom disintegrins: an outline of their interplay with integrins. Curr. Drug Targets 20, 465–477 (2019).
Calvete, J. J. The persevering with saga of snake venom disintegrins. Toxicon 62, 40–49 (2013).
Ciolek, J. et al. Inexperienced mamba peptide targets type-2 vasopressin receptor towards polycystic kidney illness. Proc. Natl Acad. Sci. USA 114, 7154–7159 (2017).
Colombo, A. L. et al. Results of the pure peptide crotamine from a South American rattlesnake on Candida auris, an emergent multidrug antifungal resistant human pathogen. Biomolecules 9, 205 (2019).
El Chamy Maluf, S. et al. Inhibition of malaria parasite Plasmodium falciparum improvement by crotamine, a cell penetrating peptide from the snake venom. Peptides 78, 11–16 (2016).
Dal Mas, C. et al. Anthelmintic results of a cationic toxin from a South American rattlesnake venom. Toxicon 116, 49–55 (2016).
Macedo, S. R. A. et al. Biodegradable microparticles containing crotamine remoted from Crotalus durissus terrificus show antileishmanial exercise in vitro. Pharmacology 95, 78–86 (2015).
Mackessy S. P. (ed.) Handbook of Venoms and Toxins of Reptiles (CRC, 2021). This e book describes the composition, bioactivity, pathophysiology and medicinal purposes of snake venom.
Salvador, G. H. M., dos Santos, J. I., Lomonte, B. & Fontes, M. R. M. Crystal construction of a phospholipase A2 from Bothrops asper venom: insights into a brand new putative “myotoxic cluster”. Biochimie 133, 95–102 (2017).
Murakami, M. T. et al. Inhibition of myotoxic exercise of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. J. Mol. Biol. 350, 416–426 (2005).
Kalita, B., Mackessy, S. P. & Mukherjee, A. Ok. Proteomic evaluation reveals geographic variation in venom composition of Russell’s viper within the Indian subcontinent: implications for scientific manifestations post-envenomation and antivenom therapy. Professional Rev. Proteomics 15, 837–849 (2018).
Favaloro, E. J. The Russell viper venom time (RVVT) take a look at for investigation of lupus anticoagulant (LA). Am. J. Hematol. 94, 1290–1296 (2019).
Chen, H.-S., Tsai, H.-Y., Wang, Y.-M. & Tsai, I.-H. P-III hemorrhagic metalloproteinases from Russell’s viper venom: cloning, characterization, phylogenetic and purposeful website analyses. Biochimie 90, 1486–1498 (2008).
Nakayama, D., Ben Ammar, Y., Miyata, T. & Takeda, S. Structural foundation of coagulation issue V recognition for cleavage by RVV-V. FEBS Lett. 585, 3020–3025 (2011).
You, W.-Ok. et al. Purposeful characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 571, 67–73 (2004).
Sousa, L. F. et al. Purposeful proteomic analyses of Bothrops atrox venom reveals phenotypes related to habitat variation within the Amazon. J. Proteom. 159, 32–46 (2017).
Núñez, V. et al. Snake venomics and antivenomics of Bothrops atrox venoms from Colombia and the Amazon areas of Brazil, Perú and Ecuador counsel the prevalence of geographic variation of venom phenotype by a pattern in direction of paedomorphism. J. Proteom. 73, 57–78 (2009).
Calvete, J. J. et al. Snake inhabitants venomics and antivenomics of Bothrops atrox: paedomorphism alongside its transamazonian dispersal and implications of geographic venom variability on snakebite administration. J. Proteom. 74, 510–527 (2011).
Kohlhoff, M. et al. Exploring the proteomes of the venoms of the Peruvian pit vipers Bothrops atrox, B. barnetti and B. pictus. J. Proteom. 75, 2181–2195 (2012).
Hatakeyama, D. M. et al. Venom complexity of Bothrops atrox (frequent lancehead) siblings. J. Venom. Anim. Toxins Incl. Trop. Dis. 26, 20200018 (2020).
Wallnoefer, H. G., Lingott, T., Gutiérrez, J. M., Merfort, I. & Liedl, Ok. R. Spine flexibility controls the exercise and specificity of a protein–protein interface: specificity in snake venom metalloproteases. J. Am. Chem. Soc. 132, 10330–10337 (2010).
Camacho, E., Escalante, T., Remans, Ok., Gutiérrez, J. M. & Rucavado, A. Web site mutation of residues in a loop surrounding the lively website of a PI snake venom metalloproteinase abrogates its hemorrhagic exercise. Biochem. Biophys. Res. Commun. 512, 859–863 (2019). This examine gives perception into the molecular-level mechanism of physiological substrate recognition by SVMPs.